Clinical characteristics and HLA associations of azithromycin-induced liver injury,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clinical characteristics and HLA associations of azithromycin-induced liver injury
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2024-07-10 , DOI: 10.1111/apt.18160
Caroline Conlon ₁ , Yi-Ju Li ₂ , Jawad Ahmad ₃ , Huiman Barnhart ₂ , Robert J Fontana ₄ , Marwan Ghabril ₅ , Paul H Hayashi ₆ , David E Kleiner ₇ , William M Lee ₈ , Victor Navarro ₉ , Joseph A Odin ₃ , Elizabeth J Phillips ₁₀ , Andrew Stolz ₁₁ , Raj Vuppalanchi ₅ , Dina Halegoua-DeMarzio ₁ ,

Affiliation

Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Duke Clinical Research Institute, Durham, North Carolina, USA.
Icahn School of Medicine at Mount Sinai, New York, New York, USA.
University of Michigan Medical School, Ann Arbor, Michigan, USA.
Indiana University School of Medicine, Indianapolis, Indiana, USA.
Division of Hepatology and Nutrition, Food and Drug Administration, Silver Spring, Maryland, USA.
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jefferson Health, Einstein Medical Center, Philadelphia, Pennsylvania, USA.
Vanderbilt University Medical Center, Nashville, Tennessee, USA.
University of Southern California Keck School of Medicine, Los Angeles, California, USA.

Azithromycin (AZ) is a widely used antibiotic. The aim of this study was to characterise the clinical features, outcomes, and HLA association in patients with drug-induced liver injury (DILI) due to AZ.

中文翻译：